Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

Slides:



Advertisements
Similar presentations
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Advertisements

O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
Endometrial Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Pelvic Masses & Ovarian Cancer. Differential diagnosis of pelvic masses Investigations and management Benign ovarian cysts Ovarian cancer.
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Endometrial Cancer Tseng Jen-Yu 02/05/2007 Tseng Jen-Yu 02/05/2007.
Tim Broadhead Consultant Gynaecologist & Gynaecological Oncologist
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.
Special Tutorial Programme Professor Deirdre J Murphy Trinity College.
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
Malignant Ovarian Tumors
OVARIAN CANCER Talking point: Genetics of ovarian cancer.
Ovarian cancer….. in 15 minutes
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Ovarian tumours.
Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Focus on Ovarian Cancer (Relates to Chapter 54, “Nursing Management: Female Reproductive Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc.,
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
Post-menopausal bleeding PV Dr Nasira Sabiha Dawood.
Ovarian Tumours Max Brinsmead MBBS PhD November 2014.
BY DR. KHANSA IQBAL SENIOR REGISTRAR GYNAE UNIT-II.
Clinico-pathological conference: Gynae Oncology Friday Dec 7 th 2007 Alex Laios, Orla Sheils, John O’Leary.
OVARIAN CANCER New NICE guidelines and the research behind them Journal Club 20/5/11 Natalie Brown and Matthew Parkes.
Quang Truong Mr. Kashub 2nd Session
Ovarian Pathology for Undergraduates Max Brinsmead MB BS PhD November 2014.
Computed tomography scan of the abdomen shows a large cystic mass in the abdomen and pelvis without solid tissue or septations (measurement: 43×20×31-cm.
TEMPLATE DESIGN © Primary Peritoneal Carcinoma found at caeserean section, value of routine abdominal examination at caeserean.
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
MRS PC, 63YO WOMAN  Initially presented with chronic RIF pain  Found to have cholelithiasis, underwent a laparoscopic cholecystectomy  On the laparoscopy,
Management of ovarian cysts
Endometrial Carcinoma
Are there benefits from chemotherapy to early endometrial cancer
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Ovarian cancer Karima salama.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
17 th century microscopes In The Name of God PARISA REZAEI,M.D.,AP.CP.
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Rahimullah Khattak Final Year MBBS  Anatomy of the Ovary  Classification  Incidence  Risk Factors  Spread and Screening  Signs and Symptoms 
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Consultant Obstetrician & Gynaecologist
부산대학교병원 김 주 연 2012 년 세포병리학회 가을학술대회 월례집담회.  F/52  Past history : 03’ left breast operation, on follow up  Lower abdominal pain (12’ April)  Physical.
Metastatic Tumors of Ovary. METASTATIC TUMOR FROM BREAST CANCER both ovaries replaced by pale, rather nodular tumor, with breast cancer cells arranged.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Synchronous Ovarian and Endometrial Carcinomas; An Unusual Outcome of First Trimester Ultrasound Scanning. Karl McPherson, Rhona Lindsay, Jaimie Thiesen-Nash,
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
End of Rotation Questions
Adjuvant chemotherapy for early stage epithelial ovarian cancer
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
The Uganda Cancer Institute Experience Walusansa Victoria.
Dr Jane Skeen- for the NZ NCCN Pacific working group
Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues
Benign and Malignant cysts and tumors of the ovary
FALLOPIAN TUBE CARCINOMA – A CASE PRESENTATION PATHOLOGICAL FINDINGS
Patient no 45 (Recent Updates)
Male and Female Reproductive Health Concerns
Malignant Ovarian Neoplasms
GEMSTONE Educational Case Summary
GEMSTONE Educational Case Summary
What is the role of genetic testing in patients with ovarian cancer?
GEMSTONE Educational Case Summary
Ovarian Cancer-Route to Diagnosis
Fallopian Tube Cancer Paweł Sadłecki
Airedale NHS Foundation Trust
Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S
Presentation transcript:

Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

Question 1 A 66 year old women underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. What is the most likely diagnosis? Click Here For Answer Serous cystadenocarcinoma Endometrioid adenocarcinoma Mucinous cystadenocarcinoma Clear cell cystadenocarcinoma Transitional cell carcinoma

Question 1 A 66 year old women underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. What is the most likely diagnosis? Click Here For Next Question Serous cystadenocarcinoma Endometrioid adenocarcinoma Mucinous cystadenocarcinoma Clear cell cystadenocarcinoma Transitional cell carcinoma

Question 2 A 66 year old women underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. What is the most important risk factor for the development of ovarian cancer? Click Here For Answer Infertility Oestrogen replacement therapy Diet / obesity Family history Talcum powder (perineal application)

Question 2 A 66 year old women underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. What is the most important risk factor for the development of ovarian cancer? Click Here For Next Question Infertility Oestrogen replacement therapy Diet / obesity Family history Talcum powder (perineal application)

Question 3 A 35 year old women complained of right sided pelvic pain and was found to have an adnexal mass. Her risk of malignancy index (RMI) was calculated. What is the correct formula? U = Ultrasound results; M = menopausal status Click Here For Answer U x age x M x Ca125 U x M x age U x M x Ca125 M x age x Ca125 U x age x Ca125

Question 3 A 35 year old women complained of right sided pelvic pain and was found to have an adnexal mass. Her risk of malignancy index (RMI) was calculated. What is the correct formula? U = Ultrasound results; M = menopausal status Click Here For Next Question U x age x M x Ca125 U x M x age U x M x Ca125 M x age x Ca125 U x age x Ca125

Question 4 A 35 year old women complained of right sided pelvic pain and was found to have an adnexal mass. Her RMI was calculated at 225. Which investigation (if any) should be performed next? Click Here For Answer No further investigation Fine needle aspirate of adnexal mass Trucut biopsy of adnexal mass CT scan of abdomen / pelvis Staging laparotomy

Question 4 A 35 year old women complained of right sided pelvic pain and was found to have an adnexal mass. Her RMI was calculated at 225. Which investigation (if any) should be performed next? Click Here For Next Question No further investigation Fine needle aspirate of adnexal mass Trucut biopsy of adnexal mass CT scan of abdomen / pelvis Staging laparotomy

Question 5 A 50 year old nurse underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. She was found to have a large right ovarian mass with cystic and solid elements, rupture of the capsule, omental deposits measuring <2cm in diameter, liver capsule deposits, a small amount of ascites and a small pleural effusion. From the information given her FIGO stage is: Click Here For Answer Stage IV Stage IIB Stage IIIA Stage IIIB Stage IIIC

Question 5 A 50 year old nurse underwent a staging laparotomy, TAH, BSO and omentectomy for ovarian cancer. She was found to have a large right ovarian mass with cystic and solid elements, rupture of the capsule, omental deposits measuring <2cm in diameter, liver capsule deposits, a small amount of ascites and a small pleural effusion. From the information given her FIGO stage is: Click Here For Next Question Stage IV Stage IIB Stage IIIA Stage IIIB Stage IIIC

Question 6 A 42 year old accountant underwent a staging laparotomy, TAH, BSO and omentectomy for a poorly-differentiated serous cystadenocarcinoma. The operation note stated that “optimal” cytoreduction was obtained. The accepted definition of “optimal” encompasses patients in whom there remain no tumour nodules greater than: Click Here For Answer 1.5cm in diameter 0.2cm in diameter 0.5cm in diameter 0.7cm in diameter 1.0cm in diameter

Question 6 A 42 year old accountant underwent a staging laparotomy, TAH, BSO and omentectomy for a poorly-differentiated serous cystadenocarcinoma. The operation note stated that “optimal” cytoreduction was obtained. The accepted definition of “optimal” encompasses patients in whom there remain no tumour nodules greater than: Click Here For Next Question 1.5cm in diameter 0.2cm in diameter 0.5cm in diameter 0.7cm in diameter 1.0cm in diameter

Question 7 A 63 year old civil servant underwent a staging laparotomy, TAH, BSO and omentectomy and was found to have a stage IIC mucinous cystadenocarcinoma of the ovary. She was offered adjuvant chemotherapy. Which drug or drug-combination is most likely to cause peripheral neuropathy? Click Here For Answer Cisplatin / pactitaxel Single agent carboplatin Carboplatin / paclitaxel Carboplatin / docetaxel Cisplatin / docetaxel

Question 7 A 63 year old civil servant underwent a staging laparotomy, TAH, BSO and omentectomy and was found to have a stage IIC mucinous cystadenocarcinoma of the ovary. She was offered adjuvant chemotherapy. Which drug or drug-combination is most likely to cause peripheral neuropathy? Click Here For Next Question Cisplatin / pactitaxel Single agent carboplatin Carboplatin / paclitaxel Carboplatin / docetaxel Cisplatin / docetaxel

Question 8 A 48 year old teacher underwent a staging laparotomy, TAH, BSO and omentectomy for suspected ovarian cancer. A large right ovarian mass with solid and cystic elements was found. Histopathology showed a clear cell carcinoma of the right ovary with a small focus of disease in the left ovary. What is the most appropriate management? Click Here For Answer Adjuvant chemotherapy with 8 cycles of carboplatin / paclitaxel Observation with serial Ca125 Adjuvant chemotherapy with 6 cycles of carboplatin Adjuvant chemotherapy with 8 cycles of carboplatin Adjuvant chemotherapy with 6 cycles of carboplatin / paclitaxel

Question 8 A 48 year old teacher underwent a staging laparotomy, TAH, BSO and omentectomy for suspected ovarian cancer. A large right ovarian mass with solid and cystic elements was found. Histopathology showed a clear cell carcinoma of the right ovary with a small focus of disease in the left ovary. What is the most appropriate management? Click Here For Next Question Adjuvant chemotherapy with 8 cycles of carboplatin / paclitaxel Observation with serial Ca125 Adjuvant chemotherapy with 6 cycles of carboplatin Adjuvant chemotherapy with 8 cycles of carboplatin Adjuvant chemotherapy with 6 cycles of carboplatin / paclitaxel

Question 9 A 40 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for stage IIIB clear cell carcinoma of the ovary. What is the most appropriate management? Click Here For Answer Observation with serial Ca125 Adjuvant chemotherapy with 6 cycles of carboplatin Adjuvant chemotherapy with 8 cycles of carboplatin Adjuvant chemotherapy with 6 cycles of carboplatin / paclitaxel Adjuvant chemotherapy with 8 cycles of carboplatin / paclitaxel

Question 9 A 40 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for stage IIIB clear cell carcinoma of the ovary. What is the most appropriate management? Click Here For Next Question Observation with serial Ca125 Adjuvant chemotherapy with 6 cycles of carboplatin Adjuvant chemotherapy with 8 cycles of carboplatin Adjuvant chemotherapy with 6 cycles of carboplatin / paclitaxel Adjuvant chemotherapy with 8 cycles of carboplatin / paclitaxel

Question 10 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is the most appropriate management? Click Here For Answer Repeat Ca125 in 8 weeks Repeat Ca125 in 6 months Repeat CT scan Chemotherapy with carboplatin / paclitaxel Chemotherapy with single agent carboplatin

Question 10 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is the most appropriate management? Click Here For Next Question Repeat Ca125 in 8 weeks Repeat Ca125 in 6 months Repeat CT scan Chemotherapy with carboplatin / paclitaxel Chemotherapy with single agent carboplatin

Question 11 A 40 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for stage IIIB clear cell carcinoma of the ovary. Which trial(s) may she be eligible for? Click Here For Answer ICON4 ICON5 ICON4, SCOTROC4 ICON5, SCOTROC4 ICON4, ICON5, SCOTROC4

Question 11 A 40 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for stage IIIB clear cell carcinoma of the ovary. Which trial(s) may she be eligible for? Click Here For Next Question ICON4 ICON5 ICON4, SCOTROC4 ICON5, SCOTROC4 ICON4, ICON5, SCOTROC4

Question 12 A 57 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for suspected ovarian cancer. Which FIGO stage is she most likely to have? Click Here For Answer I then II then III then IV II then III then I then IV III then IV then I then II III then I then IV then II IV then III then I then II

Question 12 A 57 year old woman underwent a staging laparotomy, TAH, BSO and omentectomy for suspected ovarian cancer. Which FIGO stage is she most likely to have? Click Here For Next Question I then II then III then IV II then III then I then IV III then IV then I then II III then I then IV then II IV then III then I then II

Question 13 A 59 year old woman underwent transvaginal ultrasound scanning which confirmed the presence of a semi-cystic, semi-solid mass arising from the left ovary. Her Ca125 was 70. What is her RMI from the information given? Click Here For Answer None of the above

Question 13 A 59 year old woman underwent transvaginal ultrasound scanning which confirmed the presence of a semi-cystic, semi-solid mass arising from the left ovary. Her Ca125 was 70. What is her RMI from the information given? Click Here For Next Question None of the above

Question 14 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. How would you define her disease? Click Here For Answer Chemo-sensitive Chemo-refractory Chemo-resistant Partially chemo-resistant Partially chemo-sensitive

Question 14 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. How would you define her disease? Click Here For Next Question Chemo-sensitive Chemo-refractory Chemo-resistant Partially chemo-resistant Partially chemo-sensitive

Question 15 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is the most important prognostic factor? Click Here For Answer Stage of disease Ca125 Age Extent of debulking surgery Response to platinum

Question 15 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is the most important prognostic factor? Click Here For Next Question Stage of disease Ca125 Age Extent of debulking surgery Response to platinum

Question 16 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is her overall 5-year survival rate? Click Here For Answer 10% 50% 40% 30% 20%

Question 16 A 40 year old woman receives chemotherapy for stage IIIB clear cell carcinoma of the ovary. 6 weeks following completion of ther treatment a CT scan shows no evidence of residual disease. She remains well for 9 months but her Ca125 rises from 19 to 65. She is asymptomatic. What is her overall 5-year survival rate? Click Here For Next Slide 10% 50% 40% 30% 20%

The End